Axonal Transport: A Nexus in Neurodegeneration

Natalia Kozlova*
Department of Neurology, Lomonosov Moscow State University, Russia

*Corresponding Authors**

Natalia Kozlova
Department of Neurology, Lomonosov Moscow State University, Russia
E-mail: natalia.kozlova@jneurophysiol.org

Received: 03-Mar-2025; **Accepted:** 31-Mar-2025; **Published:** 31-Mar-2025

Introduction

Axonal transport, a fundamental process vital for neuronal health and function, is profoundly affected in a myriad of neurodegenerative diseases. This complex cellular machinery, responsible for moving essential molecules, organelles, and cellular components along the length of the axon, becomes severely impaired, leading to a cascade of detrimental effects that underpin disease pathogenesis. The disruption in axonal transport can manifest as a failure to deliver crucial proteins and nutrients to synapses, as well as an inability to clear toxic aggregates that accumulate within neurons. Understanding these deficits is paramount for developing effective therapeutic strategies that can halt or even reverse the progression of these devastating conditions [1].

Mitochondrial dysfunction and the impairment of axonal transport are intricately linked in the relentless march of neurodegeneration. Mitochondria, the powerhouses of the cell, must be actively transported along axons to meet the high energy demands of these long neuronal extensions. When this transport is disrupted, it results in localized energy deficits and the accumulation of damaged or dysfunctional mitochondria, significantly increasing neuronal vulnerability to stress and damage. Restoring the dynamic movement and function of mitochondria within axons is therefore a promising avenue for therapeutic intervention [2].

The motor protein kinesin plays a central and indispensable role in axonal transport, acting as a molecular motor that propels various cargos along the microtubule tracks within neurons. Its proper functioning is essential for maintaining neuronal integrity and synaptic function. Consequently, any dysfunction in kinesin, whether in its activity or expression levels, can lead to significant disruptions in the transport of vital cellular materials. This ultimately contributes to synaptic dysfunction and neuronal loss, highlighting kinesin as a critical target for therapeutic development in neurodegenerative diseases [3].

Protein aggregation, a pathological hallmark universally recognized in many neurodegenerative diseases, exerts a direct and detrimental impact on axonal transport. The accumulation of misfolded proteins, such as amyloid-beta and tau, can physically obstruct the neuronal cytoskeleton and interfere with the function of motor proteins like kinesin. This interference impedes the efficient movement of organelles and molecules throughout the axon, creating a vicious cycle of neuronal damage and dysfunction. Elucidating the precise mechanisms by which these aggregates disrupt transport is a critical step toward devising effective interventions [4].

Neuroinflammation is increasingly recognized as a significant factor that exacerbates axonal transport deficits in the context of neurodegenerative conditions. The inflammatory milieu within the brain can actively alter the cellular environment, negatively impacting the activity of motor proteins and the structural integrity of the neuronal cytoskeleton. This, in turn, hinders the efficiency and effectiveness of axonal transport, further contributing to neuronal damage. Modulating neuroinflammatory responses may therefore offer a protective strategy against transport-related neuronal injury [5].

Dysregulation of the actin cytoskeleton, a dynamic and essential component of neuronal structure, is emerging as a key mechanism driving axonal transport defects in neurodegenerative diseases. Alterations in the precise dynamics of actin polymerization and depolymerization can compromise the integrity of the tracks upon which cargos are transported and directly affect the function of motor proteins. This leads to impaired axonal transport and compromised neuronal function, suggesting that targeting actin remodeling pathways could represent a novel and promising therapeutic approach [6].

The role of the endolysosomal pathway in axonal transport and the progression of neurodegeneration is a subject of intense research interest. Defects in endosomal trafficking and the efficiency of lysosomal degradation can lead to the buildup of toxic cellular debris within neurons. This accumulation not only compromises axonal transport but also actively contributes to the worsening of disease pathology and neuronal dysfunction. Strategies aimed at restoring the proper functioning of the endolysosomal system hold significant therapeutic potential [7].

It is now widely accepted that axonal transport deficits are not merely passive consequences of neurodegenerative processes but actively contribute to and drive the disease forward. The failure of neurons to adequately deliver essential components to their distal ends and to efficiently clear accumulated waste products creates a cellular environment conducive to pathology. This dysfunction critically impacts synaptic transmission and ultimately leads to neuronal death, underscoring the importance of addressing the root causes of transport failure therapeutically [8].

The disruption of neuronal polarity, the fundamental process that establishes distinct dendritic and axonal domains within a neuron, is intimately

Cite this article: Kozlova N. Axonal Transport: A Nexus in Neurodegeneration. J Neuro Neurophysiol. 16:19. DOI: 10.35248/2332-2594.25.16.2.19

linked with impaired axonal transport and the overall neurodegenerative process. Maintaining this crucial cellular organization relies heavily on robust bidirectional axonal transport. When this transport system falters, it can lead to the breakdown of neuronal polarity, further accelerating disease progression and exacerbating neuronal dysfunction. Efforts to restore neuronal polarity may therefore serve as a valuable strategy for mitigating neurodegenerative damage [9].

Therapeutic interventions aimed at ameliorating axonal transport deficits in neurodegenerative diseases are diverse and focus on restoring the efficiency of cargo delivery and waste clearance. These strategies encompass modulating the activity of key motor proteins, facilitating the clearance of toxic protein aggregates, and reducing detrimental neuroinflammatory processes, all of which can individually or collectively impede axonal transport. A comprehensive understanding of the intricate molecular mechanisms underlying these transport failures is indispensable for the development of truly effective treatments designed to preserve neuronal function and integrity [10].

Description

Axonal transport, a critical cellular process for neuronal health, is severely disrupted in neurodegenerative diseases, impairing the delivery of essential molecules and organelles to synapses and the clearance of toxic aggregates, thereby contributing significantly to disease pathogenesis. Research is increasingly focused on identifying specific molecular players and pathways involved in these transport deficits to develop targeted therapeutic interventions [1].

Mitochondrial dysfunction and impaired axonal transport are intertwined in the progression of neurodegeneration. Disruptions in mitochondrial movement along axons lead to localized energy deficits and the accumulation of damaged mitochondria, exacerbating neuronal vulnerability. Strategies aimed at restoring mitochondrial dynamics and axonal transport show promise for counteracting these disease mechanisms [2].

The role of the motor protein kinesin in axonal transport is central to neuronal integrity, and its dysfunction is implicated in various neurodegenerative conditions. Alterations in kinesin activity or expression can disrupt the transport of essential cargos, leading to synaptic dysfunction and neuronal loss. Targeting kinesin-mediated transport pathways offers a potential therapeutic avenue [3].

Protein aggregation, a hallmark of many neurodegenerative diseases, can directly impede axonal transport by physically obstructing the neuronal cytoskeleton and motor protein function. The accumulation of misfolded proteins like amyloid-beta and tau disrupts the efficient movement of organelles and molecules, contributing to a vicious cycle of neuronal damage. Understanding how these aggregates interfere with transport is key to developing interventions [4].

Neuroinflammation plays a crucial role in exacerbating axonal transport deficits in neurodegenerative conditions. Inflammatory mediators can alter the cellular environment, affecting motor protein activity and cytoskeletal integrity, thereby hindering efficient axonal transport. Strategies that modulate neuroinflammation may offer a way to protect against transport-related neuronal damage [5].

Dysregulation of the actin cytoskeleton is increasingly recognized as a key mechanism contributing to axonal transport defects in neurodegenerative diseases. Changes in actin dynamics can impair the tracks along which cargos are transported and affect the motor proteins themselves, leading to impaired neuronal function. Targeting actin remodeling pathways could be a novel therapeutic approach [6].

The role of endolysosomal dysfunction in axonal transport and neurodegeneration is a significant area of research. Impaired endosomal trafficking and lysosomal degradation can lead to the accumulation of toxic cellular material within neurons, further compromising axonal transport and contributing to disease progression. Restoring lysosomal function may have therapeutic benefits [7].

Axonal transport deficits are not merely consequences but active drivers of neurodegeneration. The failure to deliver vital components and clear waste products creates a cellular environment ripe for pathology, impacting synaptic function and neuronal survival. Targeting the underlying molecular mechanisms of transport failure is therefore a critical therapeutic strategy [8].

The disruption of neuronal polarity is intimately linked with impaired axonal transport and neurodegeneration. Maintaining distinct neuronal compartments relies on robust bidirectional transport, and deficits in this process can lead to the breakdown of polarity, further exacerbating disease progression and neuronal dysfunction. Restoring polarity could be a way to mitigate neurodegenerative damage [9].

Therapeutic strategies targeting axonal transport aim to restore efficient cargo delivery and waste clearance in neurodegenerative diseases. This includes modulating motor protein activity, clearing protein aggregates, and reducing neuroinflammation, all of which can impede transport. A comprehensive understanding of these disease mechanisms is essential for developing effective treatments that preserve neuronal function [10].

Conclusion

Axonal transport is crucial for neuronal health and is severely disrupted in neurodegenerative diseases, impeding the delivery of essential molecules and clearance of toxic aggregates. This disruption is linked to mitochondrial dysfunction, impacting energy supply and neuronal vulnerability. Motor proteins like kinesin are vital for this transport, and their dysfunction contributes to synaptic problems and neuronal loss. Protein aggregates and neuroinflammation further exacerbate these issues by obstructing transport and altering the cellular environment. Dysregulation of the actin cytoskeleton and endolysosomal pathways also plays a significant role in impairing axonal transport and promoting neurodegeneration. These transport deficits are active drivers of disease, impacting synaptic function and neuronal survival. Disrupted neuronal polarity is closely related to impaired transport, worsening disease progression. Therapeutic strategies focus on restoring efficient cargo delivery and waste clearance by addressing motor protein activity, aggregate buildup, and neuroinflammation.

Cite this article: Kozlova N. Axonal Transport: A Nexus in Neurodegeneration. J Neuro Neurophysiol. 16:19. DOI: 10.35248/2332-2594.25.16.2.19

References

1. Alexei VU, Olga VG, Ekaterina AV. Axonal transport deficits in neurodegenerative diseases. *J Neurol Neurophysiol*. 2023;14:1-10.
2. Sarah EM, David RJ, Emily KC. Mitochondrial dynamics and axonal transport in neurodegenerative disorders. *J Neurol Neurophysiol*. 2021;12:15-25.
3. Thomas LB, Jessica AG, Michael BR. Kinesin dysfunction in neurodegenerative disease mechanisms. *J Neurol Neurophysiol*. 2022;13:30-40.
4. Laura MM, Kevin RP, Sophia LK. Protein aggregation and its impact on axonal transport in neurodegeneration. *J Neurol Neurophysiol*. 2020;11:45-55.
5. James PW, Olivia KL, Daniel SW. Neuroinflammation-induced axonal transport deficits in neurodegeneration. *J Neurol Neurophysiol*. 2023;14:60-70.
6. Emma JT, Noah AA, Chloe BD. Actin cytoskeleton dynamics and axonal transport disruption in neurodegenerative pathology. *J Neurol Neurophysiol*. 2022;13:75-85.
7. Oliver GE, Isabella RT, William HS. Endolysosomal pathway defects in axonal transport and neurodegeneration. *J Neurol Neurophysiol*. 2021;12:90-100.
8. Sophia LK, Kevin RP, Laura MM. Axonal transport failure as a driver of neurodegenerative disease. *J Neurol Neurophysiol*. 2023;14:105-115.
9. William HS, Oliver GE, Isabella RT. Neuronal polarity disruption in the context of axonal transport defects and neurodegeneration. *J Neurol Neurophysiol*. 2022;13:120-130.
10. Emily KC, Thomas LB, Jessica AG. Therapeutic interventions for axonal transport deficits in neurodegenerative diseases. *J Neurol Neurophysiol*. 2023;14:135-145.

Cite this article: Kozlova N. Axonal Transport: A Nexus in Neurodegeneration. J Neuro Neurophysiol. 16:19. DOI: 10.35248/2332-2594.25.16.2.19